Tumor Necrosis Factor (Tnf) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tumor Necrosis Factor (TNF) is a pro-inflammatory cytokine that plays a central role in the immune response and has emerged as a critical mediator in neurodegenerative diseases.[1] Originally discovered for its ability to induce tumor cell death, TNF is now recognized as a key driver of neuroinflammation—a hallmark feature of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions.[2]
TNF is a 26-kDa transmembrane protein that can be cleaved to form a soluble 17-kDa trimeric cytokine.[3] It signals through two distinct receptors:
The balance between soluble TNF (sTNF) and transmembrane TNF (tmTNF), as well as receptor usage, determines the biological outcome of TNF signaling.[4]
TNFR1 activation triggers two major signaling cascades:
TNFR2 signaling primarily involves:[5]
In the central nervous system, TNF is produced by:[6]
TNF is a key driver of microglial activation:[7]
TNF increases blood-brain barrier (BBB) permeability:[8]
TNF is elevated in Alzheimer's disease and contributes to:[9]
TNF plays a significant role in dopaminergic neuron degeneration:[10]
TNF contributes to motor neuron injury:[11]
TNF is implicated in demyelination:[12]
Several strategies have been explored to modulate TNF signaling in neurodegeneration:
| Agent | Target | Status | Notes |
|---|---|---|---|
| Etanercept | sTNF/TNFR1 | Clinical trials | Soluble receptor fusion protein |
| Infliximab | TNF | Clinical trials | Monoclonal antibody |
| Adalimumab | TNF | Preclinical | FDA-approved for autoimmune diseases |
| Lenercept | TNF | Clinical trials | PEGylated TNF receptor |
A major challenge is achieving sufficient CNS penetration:[13]
The TNF gene (6p21.33) has several polymorphisms that affect expression:[14]
| Disease | Polymorphism | Effect |
|---|---|---|
| Alzheimer's | TNF-308 A | Increased risk in some populations |
| Parkinson's | TNF-308 A | Potential risk factor |
| ALS | TNF-308 A | May modify disease progression |
Beyond pathology, TNF has physiological roles in the CNS:[15]
Multiple trials have investigated TNF modulation in neurodegenerative diseases with mixed results. Ongoing research focuses on:
The study of Tumor Necrosis Factor (Tnf) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2008;5:45. DOI:10.1186/1742-2094-5-45
Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7(2):161-167. DOI:10.1038/nri2015
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501. DOI:10.1016/S0092-8674(0100237-9
Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83(5):793-800. DOI:10.1016/0092-8674(9590192-2
Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. 2010;9(6):482-493. DOI:10.1038/nrd3130
Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2-23. DOI:10.1016/j.neuroscience.2015.06.038
Lambertsen KL, Clausen BH, Babcock AA, et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci. 2009;29(5):1319-1330. DOI:10.1523/JNEUROSCI.5505-08.2009
de Vries HE, Blom-Roosemalen MC, van Oosten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996;64(1):37-43. DOI:10.1016/0165-5728(9500164-6
Janelsins MC, Mastrangelo MA, Oddo S, et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances Alzheimer disease-like pathology. J Neurosci. 2008;28(36):8983-8992. DOI:10.1523/JNEUROSCI.2198-08.2008
Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165(1-2):208-210. DOI:10.1016/0304-3940(9490746-3
Zhao W, Beers DR, Liao B, et al. Characterization of gene expression phenotype in ALS monocytes. JAMA Neurol. 2017;74(6):677-685. DOI:10.1001/jamaneurol.2017.0309
Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest. 1991;87(3):949-954. DOI:10.1172/JCI115102
Quan Y, Jiang CT, Shi B, et al. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF and preserving blood-brain barrier integrity. Mol Med Rep. 2018;17(5):6923-6930. DOI:10.3892/mmr.2018.8761
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94(7):3195-3199. DOI:10.1073/pnas.94.7.3195
Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006;440(7087):1054-1059. DOI:10.1038/nature04671